Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration..

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

2.

Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.

Pedrol E, Caro-Murillo AM, Castaño MA, Riera M, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Pulido F, Romero-Palacios A, Aguirrebengoa K, Vera F, Ferrer P, Blanco Ramos JR.

HIV Clin Trials. 2015 Jan-Feb;16(1):43-8. doi: 10.1179/1528433614Z.0000000001. Epub 2015 Jan 28.

PMID:
25777189
3.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration., Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

4.

Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.

Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Riera M, Pulido F, Vera F, Romero-Palacios A, Aguirrebengoa K, Portilla J, Ferrer P, Pedrol E.

HIV Clin Trials. 2013 Sep-Oct;14(5):204-15. doi: 10.1310/hct1405-204.

PMID:
24144897
5.

Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort.

Suárez-García I, Sobrino-Vegas P, Tejada A, Viciana P, Ribas M, Iribarren J, Díaz Menéndez M, Rivero M, Arazo P, Del Amo J, Moreno S; Cohort of the Spanish AIDS Research Network (CoRIS) study group..

HIV Med. 2014 Feb;15(2):86-97. doi: 10.1111/hiv.12078. Epub 2013 Sep 6.

6.

HIV testing policies for migrants and ethnic minorities in EU/EFTA Member States.

Alvarez-Del Arco D, Monge S, Caro-Murillo AM, Ramírez-Rubio O, Azcoaga-Lorenzo A, Belza MJ, Rivero-Montesdeoca Y, Noori T, Del Amo J; Study Working Group..

Eur J Public Health. 2014 Feb;24(1):139-44. doi: 10.1093/eurpub/ckt108. Epub 2013 Aug 5.

7.

Definition of advanced age in HIV infection: looking for an age cut-off.

Blanco JR, Jarrín I, Vallejo M, Berenguer J, Solera C, Rubio R, Pulido F, Asensi V, del Amo J, Moreno S; CoRIS..

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1000-6. doi: 10.1089/AID.2011.0377.

8.

[Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011].

Masiá M, Pérez-Cachafeiro S, Leyes M, López-Aldeguer J, López M, Segura F, Blanco JR, Peña A, Rodríguez F, Vera M, Del Amo J, Gutiérrez F; Grupo de estudio de riesgo cardiovascular de CoRIS..

Enferm Infecc Microbiol Clin. 2012 Nov;30(9):517-27. doi: 10.1016/j.eimc.2012.02.014. Epub 2012 Apr 30. Spanish.

PMID:
22551653
9.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration..

AIDS. 2012 Aug 24;26(13):1691-705.

10.

Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care.

Sobrino-Vegas P, Rodríguez-Urrego J, Berenguer J, Caro-Murillo AM, Blanco JR, Viciana P, Moreno S, Bernardino I, del Amo J; CoRIS..

Antivir Ther. 2012;17(1):1-8. doi: 10.3851/IMP1939.

PMID:
22267463
11.

Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses.

Yebra G, de Mulder M, Martín L, Rodríguez C, Labarga P, Viciana I, Berenguer J, Alemán MR, Pineda JA, García F, Holguín A; Cohort of the Spanish AIDS Research Network (CoRIS)..

J Clin Microbiol. 2012 Feb;50(2):407-13. doi: 10.1128/JCM.05798-11. Epub 2011 Dec 7.

12.

[The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up].

Sobrino-Vegas P, Gutiérrez F, Berenguer J, Labarga P, García F, Alejos-Ferreras B, Muñoz MA, Moreno S, del Amo J; CoRIS..

Enferm Infecc Microbiol Clin. 2011 Nov;29(9):645-53. doi: 10.1016/j.eimc.2011.06.002. Epub 2011 Aug 5. Spanish.

PMID:
21820763
13.

Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain.

Pérez Cachafeiro S, Caro-Murillo AM, Berenguer J, Segura F, Gutierrez F, Vidal F, Martinez-Perez MA, Sola J, Muga R, Moreno S; Cohort of the Spanish Aids Research Network..

Emerg Infect Dis. 2011 Jun;17(6):1116-9. doi: 10.3201/eid/1706.091810.

14.

Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections.

Dronda F, Sobrino P, Hernández-Novoa B, Caro-Murillo AM, Montero M, Iribarren JA, Sanz J, Del Mar Alonso M, Labarga P, Bernal E, Moreno S; CoRIS..

Curr HIV Res. 2011 Jun;9(4):229-36. doi: 10.2174/157016211796320324.

PMID:
21631429
15.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration., Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

16.

HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes.

Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Paparizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M; Collaboration of Observational HIV Epidemiological Research Europe..

Blood. 2011 Jun 9;117(23):6100-8. doi: 10.1182/blood-2010-08-301531. Epub 2011 Mar 2.

17.

Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS).

Yebra G, de Mulder M, Martín L, Pérez-Cachafeiro S, Rodríguez C, Labarga P, García F, Tural C, Jaén A, Navarro G, Holguín A; Cohort of Spanish AIDS Research Network (CoRIS)..

Antiviral Res. 2011 Jan;89(1):19-25. doi: 10.1016/j.antiviral.2010.10.008. Epub 2010 Nov 9.

PMID:
21070813
18.

Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.

Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients., Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange S, Riera M, Mussini C, Gutiérrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN.

Lancet. 2010 Jul 31;376(9738):340-5. doi: 10.1016/S0140-6736(10)60932-4. Epub 2010 Jul 15.

19.

[HIV infection in different age groups: Potential implications for prevention. CoRIS Cohort, Spain, 2004-2008].

Caro-Murillo AM, Gil Luciano A, Navarro Rubio G, Leal Noval M, Blanco Ramos JR; Cohorte de la Red de Investigación en Sida (CoRIS)..

Med Clin (Barc). 2010 Apr 24;134(12):521-7. doi: 10.1016/j.medcli.2009.09.053. Epub 2010 Mar 6. Spanish.

PMID:
20207371
20.

Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.

Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group., Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Chene G, Egger M.

Antivir Ther. 2009;14(8):1065-74. doi: 10.3851/IMP1462.

Supplemental Content

Loading ...
Support Center